(Total Views: 228)
Posted On: 10/26/2022 2:50:56 PM
Post# of 85

$AZN News Article - Capivasertib plus FASLODEX (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer https://marketwirenews.com/news-releases/capi...41525.html


My Twitter: WhyteStocks